*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and
About email@example.comThis author has not yet filled in any details.
So far firstname.lastname@example.org has created 25 blog entries.
*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. BiTE antibodies are showing promise as a potential new treatment option for those
Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancerlaurabbook@gmail.com2019-08-12T16:26:24-07:00
*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with
Understand the EGFR mutation in lung cancer through this discussion between Dr. Natasha Leighl of Princess Margaret Hospital in Toronto
Video: Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrowlaurabbook@gmail.com2019-07-06T12:03:57-07:00
The EGFR Resisters hosted Dr. Josh Bauml for an extremely informative Facebook Live presentation on "Next Generation Sequencing for EGFR
We are very excited to announce that the EGFR Resisters will be holding our first Research Summit in collaboration with
*June 2019* written by Ivy Elkins for Lungcancer.net I just saw my 18-year-old son graduate from high school. Although this
*June 2019* Medscape. The latest research indicates immunotherapy followed by osimertinib resulted in serious irAEs (severe immune related adverse events)
High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma email@example.comT15:25:17-07:00
*January 2019* Lung Cancer. This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and
*April 2019* Written by Tess Taft, MSW, LICSW, and oncology psychotherapist.© The feelings related to sexuality when it comes to